AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 291: H239-H250, 2006. First published February 17, 2006; doi:10.1152/ajpheart.01269.2005
0363-6135/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/1/H239    most recent
01269.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertrand, L.
Right arrow Articles by Vanoverschelde, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertrand, L.
Right arrow Articles by Vanoverschelde, J.-L.

AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B

Luc Bertrand,1 Audrey Ginion,1 Christophe Beauloye,1 Alexandre D. Hebert,1 Bruno Guigas,2 Louis Hue,2,* and Jean-Louis Vanoverschelde1,*

1Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium

Submitted 1 December 2005 ; accepted in final form 10 February 2006

Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.

diabetes; AMP-activated protein kinase; metformin; oligomycin



Address for reprint requests and other correspondence: L. Bertrand, Div. of Cardiology, Université Catholique de Louvain, Ave. Hippocrate, 55, CARD5550, B-1200 Brussels, Belgium (e-mail: bertrand{at}card.ucl.ac.be)




This article has been cited by other articles:


Home page
Circ Heart FailHome page
L. Sacca
Heart Failure as a Multiple Hormonal Deficiency Syndrome
Circ Heart Fail, March 1, 2009; 2(2): 151 - 156.
[Full Text] [PDF]


Home page
J. Cell Sci.Home page
D. J. Fazakerley, S. P. Lawrence, V. A. Lizunov, S. W. Cushman, and G. D. Holman
A common trafficking route for GLUT4 in cardiomyocytes in response to insulin, contraction and energy-status signalling
J. Cell Sci., March 1, 2009; 122(5): 727 - 734.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Gundewar, J. W. Calvert, S. Jha, I. Toedt-Pingel, S. Yong Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian, and D. J. Lefer
Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure
Circ. Res., February 13, 2009; 104(3): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. B. Hasinoff, D. Patel, and K. A. O'Hara
Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
Mol. Pharmacol., December 1, 2008; 74(6): 1722 - 1728.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K.-O. Stenslokken, S. Ellefsen, J. A. W. Stecyk, M. B. Dahl, G. E. Nilsson, and J. Vaage
Differential regulation of AMP-activated kinase and AKT kinase in response to oxygen availability in crucian carp (Carassius carassius)
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1803 - R1814.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Y. M. Chan, V. W. Dolinsky, C.-L. M. Soltys, B. Viollet, S. Baksh, P. E. Light, and J. R. B. Dyck
Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt
J. Biol. Chem., August 29, 2008; 283(35): 24194 - 24201.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Bertrand, S. Horman, C. Beauloye, and J.-L. Vanoverschelde
Insulin signalling in the heart
Cardiovasc Res, July 15, 2008; 79(2): 238 - 248.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Saeedi, H. L. Parsons, R. B. Wambolt, K. Paulson, V. Sharma, J. R. B. Dyck, R. W. Brownsey, and M. F. Allard
Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2497 - H2506.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Zhang, H. He, and J. A. Balschi
Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H457 - H466.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
C. U. Niesler, K. H. Myburgh, and F. Moore
Muscle: The changing AMPK expression profile in differentiating mouse skeletal muscle myoblast cells helps confer increasing resistance to apoptosis
Exp Physiol, January 1, 2007; 92(1): 207 - 217.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. W. Dolinsky and J. R. B. Dyck
Role of AMP-activated protein kinase in healthy and diseased hearts
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2557 - H2569.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. Zarrinpashneh, K. Carjaval, C. Beauloye, A. Ginion, P. Mateo, A.-C. Pouleur, S. Horman, S. Vaulont, J. Hoerter, B. Viollet, et al.
Role of the {alpha}2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2875 - H2883.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.